Can anticytokine therapy prevent unfavourable course of ulcerative colitis?
Abstract
Aim of investigation. To study potential of tumor necrosis factor-alpha inhibitor Remicade to prevent complications and unfavorable course of ulcerative colitis.
Material and methods. Therapeutic role of Remicade was investigated in one of three compared groups (24 patients) with unfavourable prognosis (frequent relapses, continuous course, steroid-dependency, steroid resistance) and risk of complications.
Results. Early onset of anticytokine therapy by Remicade has allowed to decrease frequency of unfavourable course from 83,3% (comparison group) and 78,3% (control group) to 12,5% and to prevent complications. Data of investigation prove, that so-called «top down» therapy with application of Remicade improves quality of life scores of patients in comparison to placebo (in 1 year) for over 18%, for 25,4% (in 2 years) and for 27,8% (in 3 years). Beneficial effect of anticytokine therapy in ulcerative colitis patients was revealed by parameters of general health, viability, mental health and social functioning.
Conclusions. In cases of the prognosis of complications and unfavourable course of disease Remicade treatment should be started in maximally early terms.
About the Authors
A. Yu. Baranovsky
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
E. A. Kondrashina
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
A. G. Kharitonov
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
References
1. Барановский А.Ю., Кондрашина Э.А., Харитонов А.Г. Прогноз неблагоприятного течения язвенного колита как показание к проведению антицитокиновой терапии // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2012. – Т. 22, № 3. – С. 63–69.
2. Барановский А.Ю., Симаненков В.И. Достижения и перспективы изучения функциональных и воспалительных заболеваний кишечника // Вестник СанктПетербургской медицинской академии последипломного образования, 2010. – Т. 2, № 2. – С. 121–134.
3. Новик А.А., Ионова Т.И. Исследование качества жизни в медицине / Под ред. Ю.Л. Шевченко. – М.: ГэотарМед, 2004. – 348 с.
4. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. – СПб-М.: Олма-Пресс, 2002. – 326 с.
5. Рукшина О.А. Клинико-морфологическое обоснование прогнозирования резистентных форм неспецифического язвенного колита: Автореф. дис. ... канд. мед. наук. – СПб, 2003. – 22 с.
6. Ardizzone S., Maconi G., Russo A. et al. Randomised controlled trial of azathioprine and 5-aminosalicylicacid for treatment of steroid dependent ulcerative colitis // Gut. – 2006. – Vol. 55. – Р. 47–53.
7. Burger D., Thomas S.J., Walsh A.J. et al. Depth of remission may not predict outcome of ulcerative colitis over 2 years // J. Crohn’s Colitis. – 2011. – Vol. 5. – Р. 4–5.
8. Cosnes J. Can we modulate the clinical course of inflam- matory bowel diseases by our current treatment strate- gies? // Dig. Dis. – 2009. –Vol. 27 (4). – Р. 516–521.
9. Cui D. Early aggressive therapy for severe extensive ulcerative colitis // World J. Gastroenterol. – 2009. – Vol. 15 (33). – Р. 4218–4219.
10. Faubion W.A., Loftus E.V., Harmsen W.S. et al. The natural history of corticosteroid therapy for inflam- matory bowel disease: a population-based study // Gastroenterology. – 2001. – Vol. 121. – Р. 255–260.
11. Feagan B.G., Reinisch W., Rutgeerts P. et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients // Am. J. Gastroenterol. – 2007. – Vol. 102 (4). – Р. 794–802.
12. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H., IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort // Gastroenterology. – 2007. – Vol. 133. – Р. 412–422.
13. Hawthorne A.B., Logan R.F., Hawkey C.J. Randomised controlled trial of azathioprine with draw al in ulcerative colitis // BMJ. – 1992. – Vol. 305. – Р. 20–22.
14. Lawson M.M., Thomas A.G., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis // Cochrane Database Syst. Rev. – 2006. – Vol. 3. – CD005112.
15. Panaccione R., Rutgeerts P., Sandborn W.J. et al. Review article: treatment algorithms to maximize remis- sion and minimize corticosteroid dependence in patients with inflammatory bowel disease // Aliment. Pharmacol. Ther. – 2008. – Vol. 28 (6). – Р. 674–688.
16. Riley S.A., Mani V., Goodman M.J. et al. Microscopic activity in ulcerative colitis: what does it mean? // Gut. – 1991. – Vol. 32. – Р. 174–178.
17. Russo E.A., Harris A.W., Campbell S. et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centers in England // Aliment. Pharmacol. Ther. – 2009. – Vol. 29. – Р. 308–314.
18. Rutgeerts P., Sandborn W.J., Feagan B.G. et al. Infliximab for induction and maintenance therapy for ulcerative colitis // N. Engl. J. Med. – 2005. – Vol. 353. – Р. 2462–2476.
19. Sandborn W.J. Step-up versus top-down therapy in the treatment of ulcerative colitis // Gastroenterol. Hepatol. – 2007. – Vol. 3 (1). – P. 16–17.
20. Sandborn W.J., Rutgeerts P., Feagan B.G. et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab // Gastroenterology. – 2009. – Vol. 137. – Р. 1250–1260.
21. Vogelaar L., Spijker A.V., Woude C.J. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease // Clin. Exp. Gastroenterol. – 2009. – Vol. 2. – P. 101–109.
Review
For citations:
Baranovsky A.Yu., Kondrashina E.A., Kharitonov A.G. Can anticytokine therapy prevent unfavourable course of ulcerative colitis? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;23(6):80-86. (In Russ.)
Views:
76
Email this article 
